|||
We specialize in guiding breakthroughs in Digital Therapeutics (DTx) innovation, including drug-device combinations (‘smart medications’), through a Systems Medicine approach.
The Aspiration-Expectation Gap: Learn more
Our preclinical in silico trial software, Dynamical Disease Assess™, along with R&D support grounded in Model-Based Systems Engineering (MBSE):
Bringing better products to market faster: We achieve both development innovation and product innovation in a single approach.
Quantitative frameworks are indispensable for drug discovery, development, regulatory approval, and clinical utilization (DDRU), with MID3 (Model-Informed Drug Discovery and Development) as the go-to methodology.
Building on this foundation specifically for Digital Therapeutics (DTx), we’ve developed ‘M2D3’: Model-Informed MBSE DTx Discovery and Development. This evolved approach not only de-risks development but, even more importantly, drives product innovation—two wins, one move.
Are you an innovator, or do you represent a pharmaceutical or consumer health company (or both)? Our solutions foster collaboration between innovators and industry leaders in pharmaceuticals and consumer health, driving impactful advancements across all modalities, indications, and pipeline stages.
Read more about our Solutions in our 3 fields of innovation and our Service and Software Offerings. — Or get in touch.
Discover the meaning behind ALTAMIRGAE.